Neonatal alloimmune thrombocytopenia

Thrombocytopenia

Volumn , Issue , 2006, Pages 223-244

  Kaplan, Cecile ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869139876     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in neonatal and thrombocytopenic purpura. Ann Intern Med 1953; 38:433-469.
2. Moulinier J. Alloimmunisation maternelle antiplaquettaire “Duzo”. Proc 6th Congr Soc Haematol 1953;817-820.
3. Shulman NR, Marder VJ, Hiller MC, Collier EM. Platelet and leukocyte isoantigens and their antibodies. Serologic, physiologic and clinical studies. In: Moore CV, Brown EB, eds. Progress in Hematology. New-York: Grune and Stratton, 1964:222-304.
4. Davoren A, McParland P, Barnes CA, Murphy WG. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002; 55:289-292.
5. Sharon R, Amar A. Maternal anti-HLA antibodies and neonatal thrombocytopenia. Lancet 1981; 1:1313.
6. Skacel PO, Contreras M. Neonatal alloimmune thrombocytopenia. Blood Rev 1989; 3:174-179.
7. Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: myth or meaningful? Transfu Med Rev 2000; 14:275-280.
8. Koyama N, Ohama Y, Kaneko K, Itakura Y, Nakamura T. Association of neonatal thrombocytopenia and maternal anti-HLA antibodies. Acta Paediatr Jpn 1991; 33:71-76.
9. Tanaka T, Umesaki N, Nishio J, et al. Neonatal thrombocytopenia induced by maternal anti-HLA antibodies: a potential side effect of allogenic leukocyte immunization for unexplained recurrent aborters. J Reprod Immunol 2000; 46:51-57.
10. Waters AH, Murphy M, Hambley H, Nicolaides K. Management of alloimmune thrombocytopenia in the fetus and neonate. In: Nance S, ed. Clinical and Basic Science Aspects of Immunohematology. Arlington, VA: American Association of Blood Banks, 1991:155-177.
11. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000; 96:1574-1581.
12. van Loghem JJ, Dorfmeijer H, van der Hart M, Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959; 4:161-169.
13. von dem Borne AEGKr, Decary F. Nomenclature of platelet specific antigens. Br J Haematol 1990; 74:239-240.
14. Newman PJ. Nomenclature of human platelet alloantigens: a problem with the HPA system? Blood 1994; 83:1447-1451.
15. von dem Borne AEGKr, Kaplan C, Minchinton R. Nomenclature of human platelet alloantigens. Blood 1995; 85:1409-1410.
16. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003; 85:240-245.
17. Simsek S, Faber NM, Bleeker PM, et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allelespecific restriction enzyme) analysis. Blood 1993; 81:835-840.
18. Liu TC, Shih MC, Lin CL, Lin SF, Chen CM, Chang JG. Gene frequencies of the HPA-1 to HPA-8w platelet antigen alleles in Taiwanese, Indonesian, and Thai. Ann Hematol 2002; 81:244-248.
19. Halle L, Bach KH, Martageix C, et al. Eleven human platelet systems studied in the Vietnamese and Ma’ohis Polynesian populations. Tissue Antigens 2004; 63:34-40.
20. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1:363-366.
21. Kaplan C, Morel-Kopp MC, Kroll H, et al. HPA-5b (Bra) neonatal alloimmune thrombocytopenia: Clinical and immunological analysis of 39 cases. Br J Haematol 1991; 78:425-429.
22. Glade-Bender J, McFarland JG, Kaplan C, Porcelijn L, Bussel JB. Anti-HPA-3a induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001; 138:862-867.
23. Kroll H, Kiefel V, Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang 1998; 74(S2):345-354.
24. Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000; 110:735-742.
25. Jallu V, Meunier M, Brement M, Kaplan C. A new platelet polymorphism Duv(aC), localized within the RGD binding domain of glycoprotein IIIa, is associated with neonatal thrombocytopenia. Blood 2002; 99:4449-4456.
26. Santoso S, Kiefel V, Richter IG, et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta(3) integrin: the Oe(a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002; 99:1205-1214.
27. Hann IM. Development of blood in the fetus. In: Hann IM, Gibson BES, Letsky E, eds. Fetal and Neonatal Haematology. London: Bailliere Tindall, 1991:1-28.
28. Pahal GS, Jauniaux E, Kinnon C, Thrasher AJ, Rodeck CH. Normal development of human fetal hematopoiesis between eight and seventeen weeks’gestation. Am J Obstet Gynecol 2000; 183:1029-1034.
29. Forestier F, Daffos F, Galacteros F, Bardakjian J, Rainaut M, Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986; 20:342-346.
30. Durand-Zaleski I, Schlegel N, Blum-Boisgard C, et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 1996; 13:423-431.
31. Valentin N, Vergracht A, Bignon JD, et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990; 27:73-79.
32. Decary F, L’Abbe D, Tremblay L, Chartrand P. The immune response to the HPA-1a antigen: association with HLA-DRw52a. Transfus Med 1991; 1:55-62.
33. A1) is strongly associated with both HLA-DR3*0101 and HLADQB1*0201. Hum Immunol 1992; 34:107-114.
34. Kuijpers RWAM, von dem Borne AEGKr, Kiefel V, et al. Leucine33-proline33 substitution in human platelet glycoprotein IIIa determines HLA-DRw52a (Dw24) association of the immune response against HPA-1a (Zwa/PlA1) and HPA-1b (Zwb/PlA2). Hum Immunol 1992; 34:253-356.
35. Maslanka K, Yassai M, Gorski J. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J Clin Invest 1996; 98:1802-1808.
36. Wu S, Maslanka K, Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J Immunol 1997; 158:3221-3226.
37. Semana G, Zazoun T, Alizadeh M, Morel-Kopp MC, Genetet B, Kaplan C. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization. Role of HLA class II and TAP genes. Hum Immunol 1996; 46:114-119.
38. Westman P, Hashemi-Tavoularis S, Blanchette V, et al. Maternal DRB1*1501, DQA1*0102, DQB1*0602 haplotype in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GP IIIa-Gln489). Tissue Antigens 1997; 50:113-118.
39. Valentin N, Visentin GP, Newman PJ. Involvement of the cystein-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 1995; 85:3028-3033.
40. Barron-Casella EA, Nebbia G, Rogers OC, King KE, Kickler TS, Casella JF. Construction of a human platelet alloantigen-1a epitope(s) within murine glycoprotein IIIa: identification of residues critical to the conformation of the antibody binding site(s). Blood 1999; 93:2959-2967.
41. Watkins NA, Schaffner-Reckinger E, Allen DL, et al. HPA-1a phenotype-genotype discrepancy reveals a naturally occrring Arg93Gln substitution in the platelet b3 integrin that disrupts the HPA-1a epitope. Blood 2002; 99:1833-1839.
42. Morel-Kopp MC, Daviet L, McGregor J, Kaplan C. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis 1996; 7:144-146.
43. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PLA1, Zwa) as determined by antenatal screening. Blood 1998; 92:2280-2287.
44. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 1997; 89:4402-4406.
45. Hohlfeld P, Forestier F, Kaplan C, Tissot JD, Daffos F. Fetal thrombocytopenia: a retrospective survey of 5194 fetal blood samplings. Blood 1994; 84:1851-1856.
46. Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988; 72:340-343.
47. Govaert P, Bridger J, Wigglesworth J. Nature of the brain lesion in fetal alloimmune thrombocytopenia. Dev Med Child Neurol 1995; 37:485-495.
48. Sharif U, Kuban K. Prenatal intracranial hemorrhage and neurologic complications in alloimmune thrombocytopenia. J Child Neurology 2001; 16:838-842.
49. Dale ST, Coleman LT. Neonatal alloimmune thrombocytopenia: antenatal and postnatal imaging findings in the pediatric brain. Am J Neuroradiol 2002; 23:1457-1465.
50. de Vries LS, Connell J, Bydder GM, et al. Recurrent intracranial haemorrhages in utero in an infant with alloimmune thrombocytopenia. Case report. Br J Obstet Gynaecol 1988; 95:299-302.
51. Giovangrandi Y, Daffos F, Kaplan C, Forestier F, Mac Alleese J, Moirot M. Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia. Lancet 1990; 336:310.
52. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001; 41:45-55.
53. Friedman JM, Aster RH. Neonatal alloimmune thrombocytopenic purpura and congenital porencephaly in two siblings associated with a “new” maternal antiplatelet antibody. Blood 1985; 65:1412-1415.
54. Sherer DM, Anyaegbunam A, Onyeije C. Antepartum fetal intracranial hemorrhage, predisposing factors and prenatal sonography: a review. Am J Perinatol 1998; 15:431-441.
55. Murphy MF, Hambley H, Nicolaides K, Waters AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn 1996; 16:1152-1155.
56. Stanworth SJ, Hackett GA, Williamson LM. Fetomaternal alloimmune thrombocytopenia presenting antenatally as hydrops fetalis. Prenat Diagn 2001; 21:423-424.
57. Kaplan C, Dreyfus M, Proulle V, Tchernia G. Thrombocytopenia in childhood. In: Gresele P, Page CP, Vermylen J, Fuster V, eds. Platelets in thrombotic and nonthrombotic disorders: pathophysiology, pharmacology and therapeutics. Cambridge: Cambridge University Press, 2002:556-568.
58. Beadling WV, Herman JH, Stuart MJ, Keashen-Schnell M, Miller JL. Fetal bleeding in neonatal alloimmune thrombocytopenia mediated by anti-PlA1 is not associated with inhibition of fibrinogen binding to platelet GPIIb-IIIa. Am J Clin Pathol 1995; 103:636-641.
59. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibodyspecific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70:1722-1726.
60. Kaplan C. Evaluation of serological platelet antibody assays. Vox Sang 1998; 74(S2):355-358.
61. Goldman M, Trudel E, Richard L. Report on the Eleventh International Society of Blood Transfusion Platelet Genotyping and Serology Workshop. Vox Sang 2003; 85:149-155.
62. Jones DC, Bunce M, Fuggle SV, Young NT, Marshall SE. Human platelet alloantigens (HPAs): PCR-SSP genotyping of a UK population for 15 HPA alleles. Eur J Immunogenet 2003; 30:415-419.
63. Bugert P, Lese A, Meckies J, Zieger W, Eichler H, Klüter H. Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms. Biotechniques 2003; 35:170-174.
64. Hurd C, Lucas G. Human platelet antigen genotyping by PCR-SSP in neonatal/fetal alloimmune thrombocytopenia. In: Goulden NJ, Steward CG, eds. Pediatric Hematology: Methods and Protocols. Totowa, NJ: Humana Press Inc, 2004:71-78.
65. Finning KM, Martin PG, Soothil PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42:1079-1085.
66. Harrison CR, Curtis BR, McFarland JG, Huff RW, Aster RH. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion 2003; 43:1398-1402.
67. Murphy MF, Verjee S, Greaves M. Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT). Br J Haematol 1999; 105:123-126.
68. Win N, Ouwehand WH, Hurd C. Provision of platelets for severe neonatal alloimmune thrombocytopenia. Br J Haematol 1997; 97:930-932.
69. Ranasinghe E, Walton JD, Hurd CM, et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001; 113:40-42.
70. Lee K, Beaujean F, Bierling P. Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002; 117:480-483.
71. Win N. Provision of random-donor platelets (HPA-1a Positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies. Vox Sang 1996; 71:130-131.
72. Massey GV, McWilliams NB, Mueller DG, Napolitano A, Maurer HM. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987; 111:133-135.
73. Kaplan C, Daffos F, Forestier F, Morel MC, Chesnel N, Tchernia G. Current trends in neonatal alloimmune thrombocytopenia: diagnosis and therapy. In: Kaplan-Gouet C, Schlegel N, Salmon Ch, Mac Gregor J, eds. Platelet Immunology: Fundamental and Clinical Aspects. Paris: John Libbey-Eurotex/ed.INSERM, 1991:267-278.
74. Reese J, Raghuveer TS, Dennington PM, Barfield CP. Breast feeding in neonatal alloimmune thrombocytopenia. J Paediatr Child Health 1994; 30:447-449.
75. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang 2003; 84:318-325.
76. Engelfriet CP, Reesink HW, Kroll H, et al. International forum: prenatal management of alloimmune thrombocytopenia of the fetus. Vox Sang 2003; 84:142-149.
77. Ghidini A, Sepulveda W, Lockwood CJ, Romero R. Complications of fetal blood sampling. Am J Obstet Gynecol 1993; 168:1339-1344.
78. Hickok DE, Mills M, the western collaborative perinatal group. Percutaneous umbilical blood sampling: results from a multicenter collaborative registry. Am J Obstet Gynecol 1992; 166:1614-1618.
79. Proulx C, Filion M, Goldman M, et al. Analysis of immunoglobulin class, IgG subclass and titre of HPA-1a antibodies in alloimmunized mothers giving birth to babies with or without neonatal alloimmune thrombocytopenia. Br J Haematol 1994; 87:813-817.
80. Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995; 90:655-660.
81. Jaegtvik S, Husebekk A, Aune B, Oian P, Dahl LB, Skogen B. Neonatal alloimmune thrombocytopenia due to anti HPA-1a antibodies:the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn.BJOG 2000; 107:691-694.
82. Miyazaki R, Ogata H, Iguchi T, et al. Comparative analyses of megakaryocytes derived from cord blood and bone marrow. Br J Haematol 2000; 108:602-609.
83. Sainio S, Javela K, Kekomäki R, Teramo K. Thrombopoietin levels in cord blood plasma and amniotic fluid in fetuses with alloimmune thrombocytopenia and healthy controls. Br J Haematol 2000; 109:330-335.
84. Cremer M, Dame C, Schaeffer HJ, Giers G, Bartmann P, Bald R. Longitudinal thrombopoietin plasma concentrations in fetuses with alloimmune thrombocytopenia treated with intrauterine PLT transfusions. Transfusion 2003; 43:1216-1222.
85. Porcelijn L, Folman CC, de Haas M, et al. Fetal and neonatal thrombopoietin levels in alloimmune thrombocytopenia. Pediatr Res 2002; 52:105-108.
86. Warwick RM, Vaughan J, Murray N, Lubenko A, Roberts I. In vitro culture of colony forming unit-megakaryocyte (CFU-MK) in fetal alloimmune thrombocytopenia. Br J Haematol 1994; 88:874-877.
87. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364-1369.
88. Birchall JE, Murphy MF, Kaplan C, Kroll H, on behalf of the European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003; 122:275-288.
89. Gaddipati S, Berkowitz RL, Lembet AA, Lapinski R, McFarland JG, Bussel JB. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol 2001; 185:976-980.
90. Murphy MF, Pullon HW, Metcalfe P, et al. Management of fetal alloimmune thrombocytopenia by weekly in utero platelet transfusions. Vox Sang 1990; 58:45-49.
91. Overton TG, Duncan KR, Jolly M, Letsky E, Fisk NM. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002; 186:826-831.
92. Yeast JD, Plapp F. Fetal anemia as a response to prophylactic platelet transfusions in the management of alloimmune thrombocytopenia. Am J Obstet Gynecol 2003; 189:874-876.
93. Viëtor HE, Hawes GE, van den Oever C, et al. Intrauterine transfusions affect fetal T-cell immunity. Blood 1997; 90:2492-2501.
94. A1. Transfus Med 1991; 1:209-216.
95. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227-228.
96. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996; 174:1414-1423.
97. Kaplan C, Murphy MF, Kroll H, Waters AH. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids-more questions than answers. Br J Haematol 1998; 100:62-65.
98. Paidas MJ, Berkowitz RL, Lynch L, et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995; 172:475-479.
99. Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transfus Med 1994; 4:281-292.
100. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001; 185:683-688.
101. Silver RM, Porter TF, Branch DW, Esplin MS, Scott JR. Neonatal alloimmune thrombocytopenia: antenatal management. Am J Obstet Gynecol 2000; 182:1233-1238.
102. Daffos F, Forestier F, Kaplan C, Cox W. Prenatal diagnosis and management of bleeding disorders with fetal blood sampling. Am J Obstet Gynecol 1988; 158:939-946.
103. Moïse KJ, Jr. Intrauterine transfusion with red cells and platelets. West J Med 1993; 159:318-324.
104. Shulman NR, Aster RH, Leithner A, Hiller MC. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in “autoimmunity”. J Clin Invest 1961; 40:1597-1620.
105. a, involved in platelet transfusion refractoriness in a Japanese man. Vox Sang 1989; 56:283-287.
106. Ishida F, Saji H, Maruya E, Furihata K. Human platelet-specific antigen, Siba, is associated with the molecular weight polymorphism of glycoprotein Ib-alpha. Blood 1991; 78:1722-1729.
107. von dem Borne AE, von Riesz E, Verheugt FW, et al. Baka, a new platelet specific antigen involved in neonatal alloimmune thrombocytopenia. Vox Sang 1980; 39:113-120.
108. Lyman S, Aster RH, Visentin GP, Newman PJ. Polymorphism of human platelet membrane glycoprotein IIb associated with the Baka/Bakb alloantigen system. Blood 1990; 75:2343-2348.
109. a (HPA-3a) to the C-terminus of platelet glycoprotein IIb heavy chain and contribution of O-linked carbohydrates. Thromb Haemost 1993; 69:485-489.
110. b platelet alloantigenic epitopes. Blood 1998; 92:3260-3267.
111. a, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 1987; 80:1624-1630.
112. Kiefel V, Santoso S, Katzmann B, Mueller-Eckhardt C. The Bra/Brb alloantigen system on human platelets. Blood 1989; 73:2219-2223.
113. Santoso S, Kiefel V, Mueller-Eckhardt C. Immunochemical characterization of the new platelet alloantigen system Bra/brB. Br J Haematol 1989; 72:191-198.
114. McFarland JG, Blanchette V, Collins J, Newman PJ, Wang R, Aster RH. Neonatal alloimmune thrombocytopenia due to a new platelet-specific alloantibody. Blood 1993; 81:3318-3323.
115. a, on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia in two families. Br J Haematol 1993; 83:306-310.
116. Wang R, McFarland JG, Kekomäki R, Newman PJ. Amino acid 489 is encoded by a mutational “hot spot” on the beta-3 integrin chain: the CA/TU human platelet alloantigen system. Blood 1993; 82:3386-3391.
117. Kuijpers RW, Simsek S, Faber NM, Goldschmeding R, van Wermerkerken RK, von dem Borne AE. Single point mutation in human glycoprotein IIIa is associated with a new platelet-specific alloantigen (Mo) involved in neonatal alloimmune thrombocytopenia. Blood 1993; 81:70-76.
118. Kroll H, Kiefel V, Santoso S, Mueller-Eckhardt C. Sra, a private platelet antigen on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia. Blood 1990; 76:2296-2302.
119. Santoso S, Kalb R, Kroll H, et al. A point mutation leads to an unpaired cysteine residue and a molecular weight polymorphism of a functional platelet beta 3 integrin subunit. The Sra alloantigen system of GPIIIa. J Biol Chem 1994; 269:8439-8444.
120. a, a new low-frequency platelet-specific antigen localized on glycoprotein IIb, is associated with neonatal alloimmune thrombocytopenia. Blood 1995; 86:1019-1026.
121. a: a new platelet-specific alloantigen on glycoprotein IIIa, involved in neonatal alloimmune thrombocytopenia. Platelets 1994; 5:289.
122. a): genetic determination of a new platelet-specific alloantigen on glycoprotein IIIa and its expression in cos-7 cells. Blood 1997; 89:2422-2428.
123. a, localized on glycoprotein IIIa, involved in neonatal alloimmune thrombocytopenia. Vox Sang 1994; 67:302-306.
124. a unravelled by SSCP analysis and direct sequencing. Br J Haematol 1997; 97:330-335.
125. Kiefel V, Vicariot M, Giovangrandi Y, et al. Alloimmunization against Iy a lowfrequency antigen on platelet glycoprotein Ib/IX as a cause of severe neonatal alloimmune thrombocytopenic purpura. Vox Sang 1995; 69:250-254.
126. Sachs UJ, Kiefel V, Bohringer M, Afshar-Kharghan V, Kroll H, Santoso S. Single amino acid substitution in human platelet glycoprotein Ibbeta is responsible for the formation of the platelet-specific alloantigen Iy(a). Blood 2000; 95:1849-1855.
127. Santoso S, Amrhein J, Hofmann HA, et al. A point mutation Thr(799)Met on the alpha(2) integrin leads to the formation of new human platelet alloantigen Sit(a) and affects collagen-induced aggregation. Blood 1999; 94:4103-4111.
128. a/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDw109 on human platelets. Blood 1995; 86:2807-2814.
129. Schuh AC, Watkins NA, Nguyen Q, et al. A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens. Blood 2002; 99:1692-1698.
130. Roberts I, Murray NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003; 88:F359-F364.